SAB Biotherapeutics, Inc. (SABS) stock
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.96−0.12 (-3.90%)
Close on Nov 13, 2026Market cap $269.32MP/E –Yield –
SAB Biotherapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
SAB Biotherapeutics's profit margin for the twelve months ending Dec 31, 2024 was -2579.0%. For fiscal 2024 it was -2579.0%, against -1884.5% the year before. The highest annual figure on record is 36.4% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -2579.0% | −694.5 |
| FY2023 | Dec 31, 2023 | -1884.5% | −1806.1 |
| FY2022 | Dec 31, 2022 | -78.4% | −50.2 |
| FY2021 | Dec 31, 2021 | -28.2% | −64.6 |
| FY2020 | Dec 31, 2020 | 36.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -9934.5% | −9531.9 |
| Q2 FY2024 | Jun 30, 2024 | -2787.7% | +5258.4 |
| Q1 FY2024 | Mar 31, 2024 | -532.1% | +733.4 |
| Q4 FY2023 | Dec 31, 2023 | -7493.8% | −7129.3 |
| Q3 FY2023 | Sep 30, 2023 | -402.6% | −205.5 |
| Q2 FY2023 | Jun 30, 2023 | -8046.1% | −7970.9 |
| Q1 FY2023 | Mar 31, 2023 | -1265.5% | −1273.9 |
| Q4 FY2022 | Dec 31, 2022 | -364.4% | −260.0 |
| Q3 FY2022 | Sep 30, 2022 | -197.1% | −169.5 |
| Q2 FY2022 | Jun 30, 2022 | -75.2% | −59.1 |
| Q1 FY2022 | Mar 31, 2022 | 8.4% | +0.0 |
| Q4 FY2021 | Dec 31, 2021 | -104.5% | – |
| Q3 FY2021 | Sep 30, 2021 | -27.7% | – |
| Q2 FY2021 | Jun 30, 2021 | -16.2% | – |
| Q1 FY2021 | Mar 31, 2021 | 8.3% | – |
See a number that looks wrong?